Credit Suisse plans accelerated return equity notes on biotech ETF

By Sarah Lizee

Olympia, Wash., Sept. 11 – Credit Suisse AG, London Branch plans to price 0% Accelerated Return Equity Securities due Oct. 21, 2019 linked to the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.

The payout at maturity will be par plus 200% of any gain in the ETF, subject to a maximum return that is expected to be at least 17.6% and will be set at pricing. Investors will be fully exposed to any decline in the ETF.

Credit Suisse Securities (USA) LLC is the underwriter.

The notes will price on Sept. 14 and settle on Sept. 21.

The Cusip number is 22551LB58.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.